22 September 2022 – Minneapolis, MN United States – Imricor Medical Systems, Inc. (Company or Imricor) (ASX:IMR), the global leader in real-time iCMR cardiac ablation products, is pleased to announce that the Company has submitted for approval to commence a real-time iCMR-guided ventricular tachycardia (VT) ablation clinical trial.

11 August 2022 – Minneapolis, United States – Imricor Medical Systems, Inc. (Company or Imricor) (ASX:IMR) the global leader in realtime interventional cardiac magnetic resonance (iCMR) cardiac ablation products, is pleased to announce it has entered into two new agreements with Siemens Healthineers that together provide Imricor the ability to deploy the Company’s new 3D mapping system on the Siemens Healthineers Magnetic Resonance Imaging (MRI) platform.

31 March 2022 – Minneapolis, United States – Imricor Medical Systems, Inc. (Company or Imricor) (ASX:IMR) the global leader in Realtime iCMR cardiac ablation products, is pleased to announce it has entered into a Development Agreement with Mammendorfer Institut für Physik und Medizin GmbH (MIPM), a leading developer and manufacturer of MRI-compatible medical devices, including an MRI-compatible external cardioverter defibrillator. MIPM … Read More

11 February 2022 – Minneapolis, United States – Imricor Medical Systems, Inc. (Company or Imricor) (ASX:IMR) the global leader in realtime iCMR cardiac ablation products, today announced the scheduled retirement of its Chief Financial Officer, Ms Lori Milbrandt, and the appointment of Mr Jonathon Gut as the incoming Chief Financial Officer.

4 January 2022 – Minneapolis, United States – Imricor Medical Systems, Inc. (Company or Imricor) (ASX:IMR) the global leader in realtime iCMR cardiac ablation products, is pleased to announce that the Henry Dunant Hospital Centre in Athens, Greece (https://www.dunant.gr/en/) is the latest institution to adopt Imricor’s iCMR ablation solutions.

28 December 2021 – Minneapolis, United States – Imricor Medical Systems, Inc. (Company or Imricor) (ASX:IMR) the global leader in realtime iCMR cardiac ablation products, is pleased to announce that the German Heart Centre Berlin (https://www.dhzb.de/en/), and the Charité Medical University, Virchow-Klinikum Campus (Charité) (https://www.charite.de/en/), both in Berlin, Germany, are the latest two institutions to adopt Imricor’s iCMR ablation solutions.

13 October 2021 – Minneapolis, United States – Imricor Medical Systems, Inc. (Company or Imricor) (ASX:IMR) the global leader in iCMR-guided cardiac ablation products, is pleased to announce that the Semmelweis University Heart and Vascular Centre in Budapest Hungary, has signed a purchase agreement with Imricor, making it the eleventh site to establish an iCMR lab to perform ablations with Imricor’s products.

30 August 2021 – Minneapolis, United States – Imricor Medical Systems, Inc. (Company or Imricor) (ASX:IMR) the global leader in MRI-guided cardiac ablation products, is pleased to announce it has entered into a Sales Distribution Agreement with NordicNeuroLab AS, a leading maker of MRI compatible in-room monitors, headquartered in Norway.

lobal leader in MRI-guided cardiac ablation products, has achieved an important milestone in its geographic expansion plans with the Company’s Advantage-MR EP Recorder/Stimulator system receiving Australian TGA approval.

2 April 2021 – Minneapolis, United States – Imricor Medical Systems, Inc. (Company or Imricor) (ASX:IMR) the global leader in MRI-guided cardiac ablation products, is pleased to announce it has entered into a Distribution Agreement with Australian-owned medical distribution company Regional Health Care Group Pty Ltd (RGCH), based in Sydney.